Bayer's Prospects Are Improving -- Market Talk

Dow Jones

May 27, 2025

1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 27, 2025 08:22 ET (12:22 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538664814"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538664814\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538664814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538664814","market":"fut","top_or_hot":-1,"title":"Bayer's Prospects Are Improving -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 08:22 ET (12:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer's Prospects Are Improving -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer's Prospects Are Improving -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-27 20:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 08:22 ET (12:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538664814","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538664814","pubTimestamp":1748348520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4007":"制药"},"translate_title":"拜耳的前景正在改善——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 08:22 ET (12:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}